In a study published in Vita, Tian et al. identify PNPT1 as a key immune checkpoint that suppresses antitumor immunity by degrading immunogenic mitochondrial double-stranded RNA (mt-dsRNA) and restricting its cytosolic release, thereby quelling the mt-dsRNA-mediated danger signaling. Combining PNPT1 inhibitor with BH3-mimetic agent can robustly activate the MAVS pathway, thereby overcoming immunotherapeutic resistance in solid tumors.
Qin et al. (Thu,) studied this question.